ERAS
Price:
$3.13
Market Cap:
$884.94M
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.[Read more]
Industry
Biotechnology
IPO Date
2021-07-16
Stock Exchange
NASDAQ
Ticker
ERAS
According to Erasca, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 868.99M. This represents a change of 97.16% compared to the average of 440.76M of the last 4 quarters.
The mean historical Enterprise Value of Erasca, Inc. over the last ten years is 1.23B. The current 868.99M Enterprise Value has changed 6.96% with respect to the historical average. Over the past ten years (40 quarters), ERAS's Enterprise Value was at its highest in in the September 2021 quarter at 1.68B. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.
Average
1.23B
Median
1.51B
Minimum
282.68M
Maximum
2.05B
Discovering the peaks and valleys of Erasca, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Enterprise Value = 2.05B
Minimum Annual Increase = -80.39%
Minimum Annual Enterprise Value = 282.68M
Year | Enterprise Value | Change |
---|---|---|
2023 | 282.68M | -4.76% |
2022 | 296.81M | -80.39% |
2021 | 1.51B | -24.72% |
2020 | 2.01B | -1.78% |
The current Enterprise Value of Erasca, Inc. (ERAS) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
697.80M
5-year avg
1.23B
10-year avg
1.23B
Erasca, Inc.’s Enterprise Value is greater than Century Therapeutics, Inc. (124.44M), greater than NGM Biopharmaceuticals, Inc. (69.72M), less than Keros Therapeutics, Inc. (2.23B), greater than Monte Rosa Therapeutics, Inc. (485.80M), less than Gracell Biotechnologies Inc. (5.63B), greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than Design Therapeutics, Inc. (334.00M), less than Edgewise Therapeutics, Inc. (3.00B), greater than C4 Therapeutics, Inc. (283.45M), greater than Mineralys Therapeutics, Inc. (527.32M), greater than Cullinan Oncology, Inc. (654.99M), greater than Sana Biotechnology, Inc. (551.82M), greater than Olema Pharmaceuticals, Inc. (543.95M), greater than aTyr Pharma, Inc. (138.44M), greater than Zentalis Pharmaceuticals, Inc. (240.73M), greater than Relay Therapeutics, Inc. (632.27M), greater than Stoke Therapeutics, Inc. (530.79M), less than Pliant Therapeutics, Inc. (875.14M), greater than Black Diamond Therapeutics, Inc. (138.77M), less than Arvinas, Inc. (1.66B),
Company | Enterprise Value | Market cap |
---|---|---|
124.44M | $122.44M | |
69.72M | $128.53M | |
2.23B | $2.75B | |
485.80M | $567.68M | |
5.63B | $989.87M | |
138.26M | $181.50M | |
334.00M | $361.81M | |
3.00B | $3.04B | |
283.45M | $276.00M | |
527.32M | $624.60M | |
654.99M | $754.63M | |
551.82M | $582.73M | |
543.95M | $578.13M | |
138.44M | $131.12M | |
240.73M | $241.59M | |
632.27M | $734.81M | |
530.79M | $678.51M | |
875.14M | $894.55M | |
138.77M | $139.20M | |
1.66B | $1.74B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Erasca, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Erasca, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Erasca, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Erasca, Inc. (ERAS)?
What is the 3-year average Enterprise Value for Erasca, Inc. (ERAS)?
What is the 5-year average Enterprise Value for Erasca, Inc. (ERAS)?
How does the current Enterprise Value for Erasca, Inc. (ERAS) compare to its historical average?